Dr. Reddy's to Release Q1 FY19 Results on July 26, 2018

Published: Jul 05, 2018

Earnings call slated for July 26, 6:30 PM IST / 9:00 AM EDT
 
 

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended June 30, 2018 on Thursday, July 26, 2018 after the Board Meeting.

Summary of Events

             
Event     Date and Time     Medium
Release of financial results     July 26th, after the Board Meeting     Email, Media, Company website, Business wire
Earnings Call     July 26th, 6:30 PM IST / 9:00 AM EDT     Hosted by the Company

(Details below)

Playback of Earnings Call     After the earnings call till August 1st     Details below
Transcript of the Earnings call     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

Press meet presentation     Will be available on the Company’s website    

URL available on Company’s website, www.drreddys.com

             

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

Play Back

The play back will be available after the earnings call, through August 1st, 2018. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and ID: 375#.

 
Conference Dial-In Numbers
Primary Number:   +91 22 6280 1219
Secondary Number:   +91 22 7115 8120
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:  

Available all over India

+91 70456 71221

International Toll Free Number:   USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

     

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180705005289/en/

Contacts

Dr. Reddy's Laboratories Ltd.
INVESTOR RELATIONS
SAUNAK SAVLA
saunaks@drreddys.com
+91-40-49002135
or
MEDIA RELATIONS
CALVIN PRINTER
calvinprinter@drreddys.com
+91-40-49002121

 

Source: Dr. Reddy's Laboratories Ltd.

Back to news